Cover
Cover | Mar. 13, 2024 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | On March 14, 2024, First Wave BioPharma, Inc. (the "Company") filed a Current Report on Form 8-K (the "Original Form 8-K") with the Securities and Exchange Commission in connection with the Company's merger with ImmunogenX, Inc. ("IMGX"). This Amendment No.1 on Form 8-K/A amends the Original Form 8-K to file (i) the financial statements of IMGX required by Item 9.01(a) of Form 8-K (the "IMGX Financial Statements"), (ii) the pro forma financial information required by Item 9.01(b) of Form 8-K (together with the IMGX Financial Statements, the "IMGX Financial Information"), and (iii) a consent from Holthouse Carlin Van Trigt LLP ("HCVT") to incorporate by reference HCVT's audit report included in the IMGX Financial Information into certain of the Company's registration statements. The IMGX Financial Information and the consent of HCVT were not included in the Original Form 8-K in reliance on the instructions to such item. Except as described above, all other information in the Original Form 8-K remains unchanged. |
Document Period End Date | Mar. 13, 2024 |
Entity File Number | 001-37853 |
Entity Registrant Name | First Wave BioPharma, Inc. |
Entity Central Index Key | 0001604191 |
Entity Tax Identification Number | 46-4993860 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 777 Yamato Road |
Entity Address, Address Line Two | Suite 502 |
Entity Address, City or Town | Boca Raton |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33431 |
City Area Code | 561 |
Local Phone Number | 589-7020 |
Written Communications | false |
Soliciting Material | true |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | FWBI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |